Joseph Chao
About
Joseph Chao is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery.
According to data from OpenAlex, Joseph Chao has authored 153 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 96 papers in Oncology, 83 papers in Pulmonary and Respiratory Medicine and 49 papers in Surgery. Recurrent topics in Joseph Chao's work include Gastric Cancer Management and Outcomes (66 papers), Cancer Immunotherapy and Biomarkers (37 papers) and Colorectal Cancer Treatments and Studies (29 papers). Joseph Chao is often cited by papers focused on Gastric Cancer Management and Outcomes (66 papers), Cancer Immunotherapy and Biomarkers (37 papers) and Colorectal Cancer Treatments and Studies (29 papers). Joseph Chao collaborates with scholars based in United States, South Korea and Japan. Joseph Chao's co-authors include Samuel J. Klempner, Marwan Fakih, Eric Van Cutsem, Dean Lim, Daniel V.T. Catenacci, Kohei Shitara, Jeffrey S. Ross, Alexa B. Schrock, Siraj M. Ali and Vincent Chung and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.
In The Last Decade
Joseph Chao
145 papers receiving 3.9k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Joseph Chao United States | 29 | 2.0k | 1.6k | 1.1k | 667 | 520 | 153 | 3.9k | ||
| Tetsuya Hamaguchi Japan | 37 | 2.3k 1.2× | 1.2k 0.7× | 804 0.8× | 1.4k 2.1× | 423 0.8× | 217 | 4.5k | ||
| Dong Bok Shin South Korea | 28 | 2.4k 1.2× | 2.5k 1.5× | 1.4k 1.3× | 504 0.8× | 344 0.7× | 112 | 4.2k | ||
| Umberto Basso Italy | 35 | 2.1k 1.0× | 1.7k 1.0× | 775 0.7× | 1.0k 1.5× | 736 1.4× | 236 | 4.7k | ||
| Simon Pernot France | 25 | 2.2k 1.1× | 1.1k 0.7× | 547 0.5× | 759 1.1× | 609 1.2× | 99 | 3.5k | ||
| Hirotoshi Hasegawa Japan | 38 | 2.9k 1.4× | 1.3k 0.8× | 2.1k 1.9× | 538 0.8× | 451 0.9× | 175 | 4.6k | ||
| Javier Sastre Spain | 39 | 4.8k 2.4× | 1.9k 1.2× | 1.2k 1.1× | 988 1.5× | 1.1k 2.1× | 177 | 6.7k | ||
| Miao‐Zhen Qiu China | 38 | 2.5k 1.3× | 1.6k 1.0× | 1.1k 1.0× | 1.6k 2.4× | 1.3k 2.4× | 165 | 4.9k | ||
| Eun Kyung Cho South Korea | 29 | 2.0k 1.0× | 2.1k 1.3× | 386 0.4× | 756 1.1× | 397 0.8× | 134 | 3.6k | ||
| Axel Grothey United States | 29 | 2.6k 1.3× | 1.4k 0.9× | 685 0.6× | 896 1.3× | 438 0.8× | 93 | 3.8k | ||
| Francesco Di Costanzo Italy | 32 | 3.5k 1.8× | 2.4k 1.5× | 693 0.6× | 715 1.1× | 690 1.3× | 167 | 5.0k |
Countries citing papers authored by Joseph Chao
Since
Specialization
Citations
This map shows the geographic impact of Joseph Chao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph Chao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph Chao more than expected).
Fields of papers citing papers by Joseph Chao
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Joseph Chao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph Chao. The network helps show where Joseph Chao may publish in the future.
Co-authorship network of co-authors of Joseph Chao
This figure shows the co-authorship network connecting the top 25 collaborators of Joseph Chao. A scholar is included among the top collaborators of Joseph Chao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph Chao. Joseph Chao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Pietrantonio, Filippo, Lisa Salvatore, Taito Esaki, et al.. (2025). Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer. Journal of Clinical Oncology. 43(19). 2147–2154.
2.
Mahuron, Kelly M., Kevin M. Sullivan, Matthew C. Hernandez, et al.. (2024). Diffuse-Type Histology Is Prognostic for All Siewert Types of Gastroesophageal Adenocarcinoma. Journal of the Korean Gastric Cancer Association. 24(3). 267–267.
3.
Méndez, Guillermo, Joseph Chao, Radim Němeček, et al.. (2024). First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study. Journal of Clinical Oncology. 42(17). 2080–2093.
4.
Botta, Gregory P., Joseph Chao, H. Ma, et al.. (2024). Metastatic gastric cancer target lesion complete response with Claudin18.2-CAR T cells. Journal for ImmunoTherapy of Cancer. 12(2). e007927–e007927.
5.
Kelly, Ronan J., Katherine M. Bever, Joseph Chao, et al.. (2023). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer. Journal for ImmunoTherapy of Cancer. 11(6). e006658–e006658.
6.
Wainberg, Zev A., et al.. (2023). Role of PD-1 Inhibitors in the Treatment of Esophagogastric Adenocarcinoma: Patient Selection and Reported Outcomes. Cancer Management and Research. Volume 15. 265–275.
7.
Cutsem, Eric Van, Maria Di Bartolomeo, Elizabeth Smyth, et al.. (2023). Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. The Lancet Oncology. 24(7). 744–756.
8.
Chao, Joseph, et al.. (2023). Evolving landscape of targeted treatment options for HER2-positive gastric/gastroesophageal adenocarcinomas.. PubMed. 21(6). 312–320.
9.
Huffman, Brandon M., Vasily N. Aushev, Joseph Chao, et al.. (2022). Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers. JCO Precision Oncology. 6(6). e2200420–e2200420.
10.
Lee, Keun‐Wook, Eric Van Cutsem, Yung‐Jue Bang, et al.. (2022). Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study. Clinical Cancer Research. 28(16). 3489–3498.
11.
Arvanitis, Leonidas, et al.. (2022). A Case Report of Immunotherapy-Resistant MSI-H Gastric Cancer with Significant Intrapatient Tumoral Heterogeneity Characterized by Histologic Dedifferentiation. Journal of Clinical Medicine. 11(12). 3413–3413.
12.
Rodin, Andréi S., Grigoriy Gogoshin, Lei Wang, et al.. (2021). Dissecting Response to Cancer Immunotherapy by Applying Bayesian Network Analysis to Flow Cytometry Data. International Journal of Molecular Sciences. 22(5). 2316–2316.
13.
Chao, Joseph, Ting-Fang He, Massimo D’Apuzzo, et al.. (2021). A Phase 2 Trial Combining Pembrolizumab and Palliative Radiation Therapy in Gastroesophageal Cancer to Augment Abscopal Immune Responses. Advances in Radiation Oncology. 7(1). 100807–100807.
14.
Lordick, Florian, Andrés Cervantes, Farshid Dayyani, et al.. (2020). P-76 A phase 1 study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE®) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction cancer. Annals of Oncology. 31. S114–S114.
15.
Wyrwicz, Lucjan, Kyung-Woo Lee, Eric Van Cutsem, et al.. (2020). 1442P Association of TMB using the Foundation Medicine Companion Diagnostic (F1CDx) with efficacy of first-line pembrolizumab (pembro) or pembro plus chemotherapy (pembro + chemo) versus chemo in patients with gastric cancer (gc) from KEYNOTE-062. Annals of Oncology. 31. S907–S908.
16.
Zhao, Dan, Samuel J. Klempner, & Joseph Chao. (2019). Progress and challenges in HER2-positive gastroesophageal adenocarcinoma. Journal of Hematology & Oncology. 12(1). 50–50.
17.
Cristea, Mihaela, Paul Frankel, Timothy W. Synold, et al.. (2019). A phase I trial of intraperitoneal nab-paclitaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity. Cancer Chemotherapy and Pharmacology. 83(3). 589–598.
18.
Schrock, Alexa B., Dean C. Pavlick, Samuel J. Klempner, et al.. (2018). Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus. Clinical Cancer Research. 24(8). 1881–1890.
19.
Choi, Audrey H., Rebecca A. Nelson, Shaila J. Merchant, et al.. (2015). Rates of lymph node metastasis and survival in T1a gastric adenocarcinoma in Western populations. Gastrointestinal Endoscopy. 83(6). 1184–1192.e1.
20.
Hardwick, Nicola, Mary Carroll, Teodora Kaltcheva, et al.. (2014). p53MVA Therapy in Patients with Refractory Gastrointestinal Malignancies Elevates p53-Specific CD8+ T-cell Responses. Clinical Cancer Research. 20(17). 4459–4470.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Tetsuya Hamaguchi Breakdown of academic impact, for papers by Dong Bok Shin Breakdown of academic impact, for papers by Umberto Basso Breakdown of academic impact, for papers by Simon Pernot Breakdown of academic impact, for papers by Hirotoshi Hasegawa Breakdown of academic impact, for papers by Javier Sastre Breakdown of academic impact, for papers by Miao‐Zhen Qiu Breakdown of academic impact, for papers by Eun Kyung Cho Breakdown of academic impact, for papers by Axel Grothey Breakdown of academic impact, for papers by Francesco Di Costanzo